Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults

Metabolism: Clinical and Experimental

Volumn 57, Issue 1, 2008, Pages 121-129

  Cenci, Maria Claudia Peixoto ^a   Conceição, Flávia Lúcia ^a   Soares, Débora Vieira ^a   Spina, Luciana Diniz Carneiro ^a   Brasil, Rosane Resende de Lima Oliveira ^a   Lobo, Priscila Marise ^a   Michmacher, Eduardo ^a   Vaisman, Mario ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; HUMAN GROWTH HORMONE; INSULIN; LIPID; SOMATOMEDIN C;

ADULT; ARTICLE; BODY COMPOSITION; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CAROTID ARTERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FEMALE; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HOMEOSTASIS; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTIMA; INTRAABDOMINAL FAT; LIPID ANALYSIS; LIPID METABOLISM; LONG TERM CARE; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; WAIST CIRCUMFERENCE;

ADULT; BLOOD GLUCOSE; BODY COMPOSITION; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED;

EID: 37049010929     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.08.015     Document Type: Article

References (65)

1. Beshyah S.A., and Johnston D.G. Cardiovascular disease and risk factors in adults with hypopituitarism. Clin Endocrinol 50 (1995) 1-15
2. Cuneo R.C., Salomon F., Magauley G.A., and Sönksen P.H. The growth hormone deficiency syndrome in adults. Clin Endocrinol 37 (1992) 387-397
3. Hew F.L., O'Neal D., Kamarudin N., et al. Growth hormone deficiency and cardiovascular risk. Baillieres Clin Endocrinol Metab 12 (1998) 199-216
4. Rosén T., Edén S., Larson G., Wilhelmsen L., and Bengtsson B.-Å. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol 129 (1993) 195-200
5. Markussis V., Beshyam A.S., Fisher C., Sharp P., Nicolaides N.A., and Johnson D.G. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 340 (1992) 1188-1192
6. Johansson J.-O., Fowelin J., Landin K., Larger I., and Bengtsson B.-Å. Growth hormone deficient adults are insulin-resistant. Metabolism 44 (1995) 1126-1129
7. Johansson J.-O., Landin K., Tengborn L., Rosén T., and Bengtsson B.-Å. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler Thromb 14 (1994) 434-437
8. Cuneo R.C., Salomon F., Wiles C.M., Hesp R., and Sönksen P.H. Growth hormone treatment in growth hormone deficient adults. II. Effects on exercise performance. J Appl Physiol 70 (1991) 695-700
9. Conceição F.L., Borjensen A., Jørgensen J.O.L., and Christiansen J.S. Growth hormone therapy in adults. Front Neuroendocrinol 22 (2001) 213-246
10. Bülow B., Hagmar L., Mikoczy Z., Nordstrom C.H., and Erfurth E.M. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol 46 (1997) 75-81
11. Rosén T., and Bengtsson B.-Å. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336 (1990) 285-288
12. Gibney J., Wallace J.D., Spinks T., et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 84 (1999) 2596-2602
13. Cuneo R.C., Judd S., Wallace J.D., et al. The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 83 (1998) 108-116
14. Götherström G., Svensson J., Koranyi J., et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass and metabolic indices. J Clin Endocrinol Metab 86 (2001) 4657-4665
15. Weaver J.U., Monson J.P., Noonan K., et al. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 80 (1995) 153-159
16. Al-Shoumer K.A.S., Gray R., Anyaoku V., et al. Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin Endocrinol 48 (1998) 795-802
17. Spina L.D.C., Soares D.V., Brasil R.R.L.O., Silva E.M.C., Lobo P.M., Conceição F.L., et al. Glucose metabolism and visceral fat in GH deficient adults: 1 year of GH replacement. Growth Horm IGF Res 14 (2004) 45-51
18. Johansson J.-O., Landin K., Johannsson G., Tengborn L., and Bengtsson B.-Å. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. J Thromb Haemost 76 (1996) 422-428
19. Hwu C.M., Kwok C., Lai T.Y., et al. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J Clin Endocrinol Metab 82 (1997) 3285-3292
20. Beshyah S.A., Henderson A., Niththyananthan R., et al. The effects of short and long term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J Clin Endocrinol Metab 80 (1995) 356-363
21. Rosenfalck A.M., Maghsoudi S., Fisker S., et al. The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. J Clin Endocrinol Metab 85 (2000) 4173-4181
22. Rosenfalck A.M., Fisker S., Hilsted J., Dinesen B., Volund A., Jorgensen J.O., et al. The effect of the deterioration of insulin sensitivity on beta-cell function in growth-hormone-deficient adults following 4-month growth hormone replacement therapy. Growth Horm IGF Res 9 (1999) 96-105
23. Svensson J., Fowelin J., Landin K., Bengtsson B.-Å., and Johansson J.-O. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 87 (2002) 2121-2127
24. Christopher M., Hew F.L., Oakley M., Rantzau C., and Alford F. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy. J Clin Endocrinol Metab 83 (1998) 1668-1681
25. Bulow B., and Erfurth E.M. A low individualized GH dose in young patients with childhood onset GH deficiency normalized serum IGF-I without significant deterioration in glucose tolerance. Clin Endocrinol 50 (1999) 45-55
26. Chrisoulidou A., Beshyah S.A., Rutherford O., et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 85 (2000) 3762-3769
27. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20 (1997) 1183-1197
28. Mathews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
29. Soares D.V., Spina L.D.C., Brasil R.R.L.O., Silva E.M.C., Lobo P.M., Salles E., et al. Carotid artery intima-media thickness and lipid profile in adults with growth hormone deficiency after long-term growth hormone replacement. Metab Clin Exp 54 (2005) 321-329
30. Friedewald W.T., Levy R.I., and Friedrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
31. Maison P., Griffin S., Nicoue-Beglah M., Haddad N., Balkau B., and Chanson P. Impact of growth-hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 89 (2004) 2192-2199
32. Despres J.-P., Lemieux I., and Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 322 (2001) 716-720
33. Bengtsson B.-A., Eden S., Lonn L., et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 76 (1993) 309-317
34. Spina L.D., Soares D.V., Brasil R.R.L.O., Lobo P.M., Conceição F.L., and Vaisman M. Glucose metabolism and visceral fat in GH deficient adults: two years of GH-replacement. Pituitary 7 (2004) 1-7
35. Rizza R.A., Mandarino L.J., and Gerich J.E. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31 (1982) 663-669
36. Groop L., Segerlantz M., and Bramnert M. Insulin sensitivity in adults with growth hormone deficiency and effect of growth hormone treatment. Horm Res 64 Suppl 3 (2005) 45-50
37. Monzillo L.U., and Hamdy O. Evaluation of insulin sensitivity in clinical practice and in research settings. Nutr Rev 61 (2003) 397-412
38. Molitch M.E., Clemmons D.R., Malozowski S., Merriam G.R., Shalet S.M., and Vance M.L. Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 91 (2006) 1621-1634
39. Yuen K.C., Frystyk J., White D.K., et al. Improvements in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone dose in adults with severe GH deficiency. Clin Endocrinol 63 (2005) 428-436
40. Johannsson G., Rosen T., and Bergtsson B.-A. Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol 47 (1997) 571-581
41. Boguszewski C.L., Meister L.H., Zaninelli D.C., and Radominski R.B. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur J Endocrinol 152 (2005) 67-75
42. Cook D.M., and Yuen K.C.J. Growth hormone dosing variables in growth hormone-deficient adults. Growth Horm IGF Res 16 (2006) 49-54
43. Pfeifer M., Verhovec R., Zizek B., Prezelj J., Poredos P., and Clayton R.N. Growth (GH) hormone treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 84 (1999) 453-457
44. Borson-Chazot F., Serusclat A., Kalfallah Y., et al. Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency. J Clin Endocrinol Metab 84 (1999) 1329-1333
45. Colao A., Di Somma C., Rota F., et al. Short-term effect of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. J Clin Endocrinol Metab 90 (2005) 2056-2062
46. O'Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A., Burke G.L., and Wolfson Jr. S.K. Carotid-artery intima media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340 (1999) 14-22
47. Rudling M., Norstedt G., Olivecrona H., Reihnér E., Gustafsson J.-Å., and Angelin Bo. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci U S A 89 (1992) 6983-6987
48. Christ E.R., Cummings M.H., and Russel-Jones D.L. Dyslipidaemia in adult growth hormone (GH) deficiency and the effect of GH replacement therapy: a review. Trends Endocrinol Metab 9 (1998) 200-206
49. Attanasio A.F., Bates P.C., Ho K.K.Y., et al. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status-3-year results from the HypoCCS Database. J Clin Endocrinol Metab 87 (2002) 1600-1606
50. O'Neal D.N., Hew F.L., Best J.D., and Alford F. The effect of 24 months recombinant human growth hormone (rh-GH) on LDL cholesterol, triglyceride-rich lipoproteins and apo[a] in hypopituitary adults previously treated with conventional replacement therapy. Growth Horm IGF Res 9 (1999) 165-173
51. Garry P., Collins P., and Devlin J.D. An open 36-month study of lipid changes with growth hormone in adults: lipid changes following replacement of growth hormone in adults acquired growth hormone deficiency. Eur J Endocrinol 134 (1996) 61-66
52. Scharnagl H., Nauck M., Wieland H., and Marz W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med 39 (2001) 426-431
53. Walldius G., and Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 255 (2004) 188-205
54. Webster J.M., Stewart M., Al-Maskari M., et al. The effect of growth hormone replacement therapy for up to 12 months on lipoprotein composition and lipoprotein (a) in growth hormone-deficient adults. Atherosclerosis 133 (1997) 115-121
55. Sesmilo G., Biller B.M.K., Llvadot J., Hayden D., Hanson G., Rifai N., et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency: a randomized, controlled clinical trial. Ann Intern Med 133 (2000) 111-122
56. Johannsson G., Oscarsson J., Rosén T., et al. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and apo(a) and apoE phenotypes. Arterioscler Thromb Vasc Biol 15 (1995) 2142-2150
57. Cuneo R.C., Salomon F., Watts G.F., Hesp R., and Sönksen P.H. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 42 (1993) 1519-1523
58. Modigliani E., Kerchouni R., Uzzan B., Valensi P., Chanson P., and Caron J. Modification of blood lipids and lipoproteins after human growth hormone treatment in adults with growth hormone deficiency: a preliminary report. Endocrinol Metab 1 Suppl A (1994) 31-35
59. White A.L., Graham D.L., LeGros J., Pease R.J., and Scott J. Oleate-mediated stimulation of apolipoprotein B secretion from rat hepatoma cells. A function of the ability of apolipoprotein B to direct lipoprotein assembly and escape presecretory degradation. J Biol Chem 267 (1992) 15657-15664
60. Zhang Y.L., Hernandez-Ono A., Ko C., Yasunaga K., Huang L.S., and Ginsberg H.N. Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids. I. Differential response to the delivery of fatty acids via albumin or remnant-like emulsion particles. J Biol Chem 279 (2004) 19362-19374
61. Sedlis S.P., Shechtman K.B., Ludbrook P.A., Sobel B.E., and Schonfeld G. Plasma apoproteins and the severity of coronary artery disease. Circulation 73 (1986) 978-986
62. Sniderman A.D., Furberg C.D., Keech A., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361 (2003) 777-780
63. Thompson A., and Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 259 (2006) 481-492
64. Walldius G., Aastveit A.H., and Jugner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med 259 (2006) 259-266
65. Sierra-Johnson J., Somers V.K., Kuniyoshi F.H., Garza C.A., Isley W.L., Gami A.S., et al. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am J Cardiol 98 (2006) 1369-1373